FibroBiologics (FBLG) Profit After Tax (2023 - 2026)

FibroBiologics has reported Profit After Tax for 4 years, with the latest figure at -$4.1 million in Q2 2026.

• Profit After Tax for Q2 2026 came in at -$4.1 million, up 11.61% year-over-year; the trailing twelve-month figure through Jun 2026 was -$18.1 million (down 37.18% YoY), and the FY2025 annual result was -$18.6 million, down 67.06% from the prior year.
• Profit After Tax advanced to -$4.1 million in Q2 2026, from -$5.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $898000.0 in Q2 2024 and troughed at -$9.7 million in Q4 2023.
• A 4-year average of -$4.0 million and a median of -$3.7 million in 2025 frame the typical range for Profit After Tax.
• The widest annual swing landed in 2024, when Profit After Tax surged 141.57%; it then slumped 1055.6% in 2025.
• A 4-year view of Profit After Tax shows it stood at -$9.7 million in 2023, then jumped by 68.11% to -$3.1 million in 2024, then slipped by 4.68% to -$3.2 million in 2025, then dropped by 26.91% to -$4.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$4.1 million in Q2 2026, -$5.0 million in Q1 2026, and -$3.2 million in Q4 2025.